Can Cholesterol Be Too Low?
Lowering bad (LDL) cholesterol reduces the risk of heart disease. But some have expressed concerns over the health effects of lowering LDL cholesterol too much.
FDA Approves First Absorbable Stent
The US Food and Drug Administration (FDA) has approved the first absorbable stent for coronary artery disease (CAD).
Statins and Your Heart
For those with ischemic heart disease, statins are recommended. But not all patients may benefit from statins, according to a new JAMA Internal Medicine study.
Breast Cancer Rx and Heart Disease Risk
Researchers have known little about the use of aromatase inhibitors and heart disease risk in breast cancer survivors — until now.
Surgery Might Help Some Heart Patients
Heart failure patients with clogged arteries had a better chance of surviving 10 years if they had bypass surgery and took medications, as opposed to just taking medications, a new study found.
Take Heart: Low T Treatment Didn't Hurt Arteries
More and more men are receiving testosterone treatment as they age, leading to more and more questions about the benefits and risks of this practice. One such question might have just gotten an answer.
Weighing the Benefits of Statins
Cholesterol medication can be lifesaving for older patients, but that doesn't mean taking it is risk-free.
How to Talk with Your Doctor About Statins
Heads or tails? Chocolate or vanilla? Life is full of decisions — even for doctors. A good discussion allows patients to share in the decision-making process for their health care.
Parents Smoking Might Be Heartbreaker for Kids
Many parents may try to step away from their children when they smoke, but children exposed to even small amounts of smoke may grow up to have heart problems.
Lilly Provides Update on Evacetrapib Phase 3 Trial
INDIANAPOLIS, Feb. 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months.